The mitotic arrest deficient 2 (MAD2) is suggested to play a key role in a functional mitotic checkpoint because of its inhibitory effect on anaphase-promoting complex/cyclosome (APC/C) during mitosis. The binding of MAD2 to mitotic checkpoint regulators MAD1 and Cdc20 is thought to be crucial for its function and loss of which leads to functional inactivation of the MAD2 protein. However, little is known about the biological significance of this MAD2 mutant in human cells. In this study, we stably transfected a C-terminal-deleted MAD2 gene (MAD2DC) into a human prostate epithelial cell line, Hpr-1 and studied its effect on chromosomal instability, cell proliferation, mitotic checkpoint control and soft agar colony-forming ability. We found that MAD2DC was able to induce aneuploidy through promoting chromosomal duplication, which was a result of an impaired mitotic checkpoint and cytokinesis, suggesting a crucial role of MAD2-mediated mitotic checkpoint in chromosome stability in human cells. In addition, the MAD2DC-transfected cells displayed anchorage-independent growth in soft agar after challenged by 7,12-dimethylbenz[A]anthracene (DMBA), demonstrating a cancer-promoting effect of a defective mitotic checkpoint in human cells. Furthermore, the DMBA-induced transformation was accompanied by a complete loss of DNA damage-induced p53 response and activation of the MAPK pathway in MAD2DC cells. These results indicate that a defective mitotic checkpoint alone is not a direct cause of tumorigenesis, but it may predispose human cells to carcinogen-induced malignant transformation. The evidence presented here provides a link between MAD2 inactivation and malignant transformation of epithelial cells.
Introduction
Mitotic checkpoint or spindle assembly checkpoint is the key cell cycle control mechanism that ensures accurate chromosome segregation and production of genetically identical daughter cells. Therefore, a functional mitotic checkpoint is thought to be essential for maintaining chromosomal stability in eukaryotic cells (Kops et al., 2005) . It is believed that an impaired mitotic checkpoint may account for aneuploidy in mammalian cells, which contributes to the development of human cancer. For example, cells from mice with weakened mitotic checkpoint due to heterozygous loss of key mitotic checkpoint genes show increased frequency of aneuploidy (Michel et al., 2001; Babu et al., 2003; Dai et al., 2004) . Significant percentage of those mice develop spontaneous tumors (Michel et al., 2001; Baker et al., 2004) as well as elevated rates of carcinogen-induced tumorigenesis (Babu et al., 2003; Dai et al., 2004) . Recently, high frequency of mutations in one of the key mitotic checkpoint genes, Bub1B, was reported in a rare recessive disorder, mosaicvariegated aneuploidy, which is characterized by an increase in aneuploidy and childhood cancers (Hanks et al., 2004) . The fact that gains or losses of chromosomes are the most frequent events in human cancer samples and human cancer cell lines (Kops et al., 2005) suggests a clear positive role of chromosome instability (CIN) in the development of human cancer.
The mitotic checkpoint is well conserved in all eukaryotes, and two main groups of genes including mitotic arrest deficient (MAD) and budding uninhibited by benzimidazole (BUB) have been identified (Skibbens and Hieter, 1998) . The direct link between mitotic checkpoint and cell survival has been reported in mouse models. Homozygous deletion of the MAD2 gene in mice leads to embryonic lethality as a result of severe chromosome missegregation and massive apoptosis (Dobles et al., 2000) , indicating mitotic checkpoint is required for embryonic viability. However, the MAD2-null mouse embryonic fibroblast cells are able to survive by further deletion of the p53 gene (Burds et al., 2005) , suggesting that additional genetic changes may be required for the survival of cells with complete loss of mitotic checkpoint control. Interestingly, cells derived from MAD2 þ /À mice not only show a defective mitotic checkpoint, but also a premature sister chromatid segregation as well as aneuploidy (Burds et al., 2005) . In addition, majority of the mice also develop high frequency of tumors after a long latency (Michel et al., 2001 ). These results demonstrate a first direct link between mitotic checkpoint defect and tumorigenesis in rodent cells. Recently, decreased MAD2 expression has been reported in several types of human cancer cell lines derived from lung (Takahashi et al., 1999) , breast (Li and Benezra, 1996) , ovarian (Wang et al., 2002) and nasopharyngeal (Wang et al., 2000) carcinomas, which is correlated with an impaired mitotic checkpoint. Loss of heterozygosity at chromosome 4q27, where MAD2 is mapped (Krishnan et al., 1998) , has been reported in several types of human cancer such as Hodgkin's disease, hepatocellular carcinoma and lung cancer (Dohner et al., 1992; Rashid et al., 1999; Cho et al., 2002; Johannsdottir et al., 2004) , indicating the association between aberrant MAD2 expression and tumorigenesis. In addition, inactivation of MAD2 through microinjection of anti-MAD2 antibodies into HeLa cells results in abolishment of the nocodazole-induced mitotic arrest and premature mitosis (Gorbsky et al., 1998) . Deletion of one allele of the MAD2 gene in a human colon cancer cell line leads to a defective mitotic checkpoint and aneuploidy (Michel et al., 2001) . In contrast, transfection of MAD2 in ovarian cancer cells with low MAD2 expression results in restoration of mitotic checkpoint. These results further suggest an essential role of MAD2 in a functional mitotic checkpoint and prevention of CIN in human cells.
At a molecular level, the mitotic checkpoint blocks the ubiquitin ligase activity of anaphase-promoting complex/ cyclosome (APC/C) in response to a single chromatid that is not properly attached to the mitotic spindle in a mitotic cell, resulting in a delayed separation of sister chromatids and mitotic exit (Wang et al., 2002; Nasmyth, 2005) . Although precise molecular mechanisms responsible for mitotic checkpoint are not clear, recently, it is suggested that the mitotic checkpoint complex (MCC) containing BubR1, Bub3, MAD2 and Cdc20 on the kinetochore of the misaligned chromatid is responsible for generating the 'wait' signal (Sudakin et al., 2001; Fang, 2002; Millband and Hardwick, 2002) . Evidence so far indicates that MAD2 plays a key role in the function of this checkpoint because of its crucial role in the inhibitory effect of MCC on the activity of APC/C (Sudakin et al., 2001) . The binding of MAD2 to Cdc20, an activator of APC/C, is required for a mitotic arrest because the MAD2 bound Cdc20 is no longer capable of activating the APC/C (Zhang and Lees, 2001) . MAD2 also interacts with MAD1, which is required for recruiting MAD2 to unattached kinetochores and necessary for binding efficiency between MAD2 and Cdc20 (Sironi et al., 2001) . Recently, when an MAD2 mutant with 10 residues deleted in the C terminal (MAD2DC), which is unable to bind either MAD1 or Cdc20 (Luo et al., 2004) , is expressed in a mitotic competent cell line, HeLa, it fails to induce a mitotic arrest in the presence of spindle disruption (De et al., 2005) , indicating the importance of the interaction between MAD2 and MAD1 and Cdc20 in regulating mitosis. However, little is known about the biological effect of MAD2DC on CIN, cell proliferation or tumorigenesis in human cells.
To explore the role of MAD2-mediated mitotic checkpoint in the tumorigenicity, in this study, we inactivated the MAD2 gene through transfection of a dominant-negative MAD2DC construct in a human papillomavirus (HPV) E6/E7-immortalized prostate epithelial cell line, Hpr-1, and studied its effect on cell proliferation, mitotic checkpoint control, chromosomal stability and soft agar colony-forming ability. Our results provide first evidence to demonstrate that inactivation of MAD2 in human prostate epithelial cells was able to promote soft agar growth through induction of premature mitosis and aneuploidy.
Results
MAD2DC expression leads to aneuploidy, but not cell proliferation in human prostate epithelial cells To study the significance of MAD2DC on chromosomal instability in human epithelial cells, we transfected a Flagtagged MAD2DC expression vector into an HPV E6/E7-immortalized human prostate epithelial cell line, Hpr-1, which expresses endogenous MAD2 protein and exhibits a functional mitotic checkpoint. As shown in Figure 1a Next, we studied if the MAD2DC-induced aneuploidy in the human prostate epithelial cells was able to promote cell proliferation. However, we did not observe any significant difference in 5-bromo-2 0 -deoxyuridine (BrdU) incorporation rate ( Figure 1c ) and cell growth rate (Figure 1d ) between the vector control and the MAD2DC cells. In contrast, a high percentage of MAD2DC cells showed flattened and enlarged morphology, which was associated with a positive staining of b-galactosidase (b-gal; Figure 1e ). These results suggest that significant number of MAD2DC cells are unable to proliferate as the result of severe chromosomal instability leading to senescence, which may also explain why we did not detect any significant increase in cell proliferation rate in the MAD2DC cells.
MAD2DC leads to chromosomal amplification
One of the mechanisms responsible for polyploidy is a failure in cytokinesis leading to duplication of chromosomes in daughter cells. To study if the MAD2DC-induced aneuploidy was the result of chromosomal amplification, we performed spectral karyotyping (SKY) analysis. As shown in Figures 2a and b , in pBabe cells (purple columns), majority of chromosomes (21/23; 91%) showed two copies in a metaphase cell, with exception of chromosomes 9 and 20, which showed three copies per cell (see pink arrows). In contrast, in MAD2DC cells (blue columns), majority of chromosomes (20/23; 87%) showed three or more copies, while only three chromosomes (chr.13, 22, X) showed two copies per cell (see blue arrows). Further analysis revealed that chromosome numerical changes were observed in high percentage of MAD2DC cells (Figure 2c , blue columns), but it was a rare event in pBabe cells (purple columns). Structural analysis showed that identical chromosomal alterations were found in both cell lines (that is, del(3p), der(20)dup(20)t(20;22) , see color-coordinated circles in Figure 2a ), indicating that they were both derived from same parental cells. Additional structural alterations were also observed on five chromosomes in high percentage (35-75%) of MAD2DC cells (blue columns, Figure 2c ). These results suggest that the MAD2DC-induced aneuploidy is predominantly associated with chromosomal amplification in human epithelial cells.
MAD2DC promotes mitotic progression of polyploidy cells
It is possible that a compromised mitotic checkpoint control may provide a survival advantage for the MAD2DC cells leading to establishment of hypotetraploidy and chromosomal instability. To test this hypothesis, we treated the cells with nocodazole and studied cell cycle distribution by flow cytometry. As shown in Figure 3a , as expected, majority of pBabe cells showed a 2N DNA content under untreated conditions and accumulated at G 2 /M phase with a 4N DNA content, suggesting a functional mitotic checkpoint. To agree with the karyotyping and SKY results, majority of MAD2DC cells showed a near 4N DNA under untreated conditions, indicating again hypotetraploidy ( Figure 3a , 0 h). After treatment with nocodazole, however, the MAD2DC cells were arrested initially at G 2 /M phase with a 8N DNA content, but this arrest was overcome by 18 h. There was a further accumulation of cells with 8N DNA content at 24 h followed by cell cycle progression at 36 h. Western blotting analysis ( Figure 3b ) on the expression of cyclin A, cyclin B and p-histone H3 proteins also supported the flow cytometry results that the sustained accumulation of phosphorylated histone H3, which is necessary for chromosome condensation during mitosis, was found in the pBabe cells, but two transient expression peaks of this protein were found in the MAD2DC cells ( Figure 3b ). We also noticed a lack of correlation between flow cytometric analysis and the expression of p-histone H3. It may be due to the fact that these two experiments demonstrated different stages of mitosis. Mitosis is divided into several phases from prophase to cytokinesis, at which stage all of the cells show a 4N DNA content. In contrast, the accumulation and degradation of cyclin B1, cyclin A and p-histone H3 reflect different phases of mitosis more precisely. For example, P-histone H3 accumulates during prophase with its peak at metaphase, and then decreases when cells progress through the cell cycle to telophase. Nevertheless, these results showed that the polyploid MAD2DC cells were able to complete cytokinesis and cell cycle progression in the presence of microtubule disruption. These results are unexpected because previous MAD2 depletion studies showed that the MAD2-deficient cells were able to escape mitosis, but failed to undergo cell division resulting in polyploidy (Gorbsky et al., 1998; Michel et al., 2001) .
Amplification of centrosomes is often observed in polyploid cells which could be the result of centrosome duplication during S phase or failed cytokinesis (Rajagopalan and Lengauer, 2004) . Next, we examined centrosome status by fluorescent staining using an antibody against g-tubulin (Figure 3c ). However, we did not observe any significant difference in centrosome copy numbers between the pBabe and MAD2DC cells under routine culture conditions (left graph). However, after exposure to nocodazole, the percentage of cells containing multiple centrosomes (more than three copies) was higher in the MAD2DC cells (right graph, solid columns, *Po0.05).
MAD2DC promotes carcinogen-induced transformation
Previously, it was reported that tetraploid p53À/À mouse cells were unable to grow in soft agar, however, subcutaneous tumors were developed in nude mice after exposure to a mutagen, 7,12-dimethylbenz[A]anthracene (DMBA) (Fujiwara et al., 2005) . In addition, mice harboring heterozygous MAD2 gene deletion developed lung tumors much later in life (Michel et al., 2001 ). This suggests that in addition to tetraploidy and mitotic checkpoint defect, additional genetic alterations are necessary for malignant transformation. To test this hypothesis, we treated the transfectants with DMBA (500 and 1000 ng/ml) for 3 days and then the tumor-promoter 12-O-tetradecanoylphorbol-3-acetate (TPA) (100 ng/ml) for 10 days. Soft agar colony-formation assay showed that after 2-month culture, while there was no evidence of anchorage-independent growth in the pBabe cells treated with DMBA alone, TPA alone or DMBA þ TPA, the MAD2DC cells were able to form colonies in soft agar after treated with both DMBA and TPA (Figure 4a ). The colony-forming ability was dependent on DMBA concentrations as higher DMBA dose (1000 ng/ml) produced higher colony-forming efficiency than the lower dose (that is, 0.23 vs 0.32%). When the soft agar colonies were cultured as monolayers, the MAD2DC-agar cells (a pool of MAD2DC-agar500 and MAD2DC-agar1000 cells) showed morphological changes associated with malignant transformation such as irregular cell size and elongated morphology (Figure 4b , left panels). However, BrdU incorporation assay (Figure 4b , top right panel) and 3-2,5-diphenyltetrazolium bromide (MTT) assay (bottom right panel) failed to demonstrate any significant difference between the MAD2DC-agar cells, MAD2DC-transfected cells and pBabe controls, indicating that the MAD2DC-induced transformation is not associated with increased cell proliferation rate.
To investigate if the MAD2DC-induced anchorageindependent growth was associated with a further increased chromosomal instability, we then performed chromosome count on MAD2DC-agar cells and compared with MAD2DC and pBabe cells. As shown in Figure 4c , numerical analysis demonstrated that both MAD2DC cell lines showed similar chromosome distribution with majority (>85%) of cells containing 71-80 chromosomes and a small percentage showed chromosome number between 51 and over 100. SKY analysis (Figure 2a , bottom panel and Figure 2b ) revealed that similar to observed in MAD2DC cells, majority of chromosomes in MAD2DC-agar cells revealed amplification. Further numerical and structural analysis (Figures 2c and d) indicated that while the MAD2DC-agar cells retained majority of the structural changes observed in the MAD2DC cells (that is, del(3p); der(20)dup(20)t(20;22), see color-coordinated circles), additional structural changes were also found. For example, der(1)t(1;16) was observed in over 87% of the MAD2DC-agar cells while this aberration was not detected in the MAD2DC cells (see white circles in Figure 2a ). Since the carcinogenic effect of DMBA is believed to be through its mutagenic effect on the genome (Stewart et al., 2004) , it is not a surprise to observe the increased chromosomal structural alterations in the MAD2DC-agar cells. Cell cycle analysis revealed a similar pattern between MAD2DC and MAD2DC-agar cells before and after exposure to nocodazole (Figure 3a) and suggested that the polyploidy MAD2DC-agar cells were also able to undergo cell division in the presence on microtubule disruption. Western blotting analysis on the expression levels of cyclin B and p-histone H3 also agree with the flow cytometry results (Figure 4d ). Centrosome analysis also failed to show any significant difference between MAD2DC and MAD2DC-agar cells (Figure 3c ) before (left panel) or after (right panel) treatment with nocodazole.
Role of p53 and MEK pathways in the MAD2DC-induced transformation Carcinogens such as DMBA promotes tumorigenesis through inactivation of tumor suppressor pathways such as the p53 pathway possibly through induction of gene mutations (Stewart et al., 2004) . Although the HPV E6 oncogene is able to inactivate p53 through premature degradation of this protein (Kessis et al., 1993) , a functional p53 pathway has been reported in certain HPV E6/E7-immortalized cell lines (Butz et al., 1995) . In this study, we found the p53 protein as well as its downstream p21
Waf1 protein levels were increased in both pBabe and MAD2DC cell lines in response to a DNA damaging agent, cisplatin, (Figure 5a ), indicating a functional p53 pathway. But the fact that we only observed p53 upregulation after treating the cells with a relatively high dose of cisplatin (0.1 mg/ml) for a relatively long exposure time (48 h) indicates that the presence of HPV E6 in Hpr-1 cells may play a negative role for its function. In contrast, in MAD2DC-agar cells, neither the expression of p53 nor p21
Waf1 was significantly altered in response to cisplatin, suggesting a nonfunctional p53-mediated DNA damage response (Figure 5a ). In addition, expression of g-H2AX, an indicator of DNA double-strand break accumulation (Rogakou et al., 1998) , was much higher in the MAD2DC-agar cells compared to the MAD2DC or pBabe cell lines, further indicating an insufficient DNA repair ability in the MAD2DC-agar cells. Furthermore, we also observed that the basal levels of the p53 protein were also increased in the MAD2DC-agar cells (Figure 5a ). It is possible that DMBA treatment may have caused mutations on the p53 gene as previously reported (Stewart et al., 2004) which leads to stabilization of this protein. However, sequencing analysis of the p53 gene showed no evidence of mutation, suggesting that the increased p53 expression is not the result of DMBA-induced mutation. Similar results were also reported previously that in a DMBA-induced breast cancer animal model and a skin carcinogenesis model, increased p53 protein was observed but mutations of the p53 gene were not found (Jerry et al., 1994; Zhao et al., 2006) . Although the precise mechanism responsible for the DMBA-induced p53 activation is not clear, activation of the Ras pathway by DMBA is suggested to play a role (Zhao et al., 2006) . In this study, the fact that the level of H2AX was also higher in the untreated MAD2DC-agar cells further suggests an increased spontaneous DNA damage rate, possibly as a consequence of a nonfunctional p53-mediated DNA damage response.
Activation of the MAPK pathway is believed to provide growth advantage necessary for malignant progression (Sebolt-Leopold, 2000) and in prostate cancer activation of MAPK signaling pathway is reported to be associated with progression of this cancer (Eid et al., 1998; Gioeli et al., 1999) . We also found an increased activation of two key regulators of the MAPK pathway, phosphorylated MEK1/2 and ERK1/2 in the MAD2DC cells. As shown in Figure 5b , while the phosphorylated MEK1/2 and ERK1/2 were barely detectable in pBabe cells, their expression levels were moderately increased in MAD2DC cells and much higher in the MAD2DC-agar cells. Previously, it has been reported that DMBA/TPA induces mutational activation of the Ras gene (Osaka et al., 1995) which plays a key role in activation of the MAPK pathway. To investigate if activation of the MEK/ERK was the result of Ras mutation caused by DMBA/TPA treatment, we sequenced the Ras gene in all four cell lines using primers amplifying first 61 codons of the H-, K-and N-Ras genes, respectively. However, no mutations were identified in any of the cell lines.
Discussion
Although several previous studies have reported the association between loss of MAD2-mediated mitotic checkpoint and tumorigenesis in rodent cells (Michel et al., 2001; Burds et al., 2005) , the current study demonstrates in human epithelial cells that inactivation of mitotic checkpoint leads to polyploidy and promotes malignant transformation. Our results also suggest that inactivation of MAD2 through disrupting its binding to MAD1 and Cdc20 leads to suppression of its function as a mitotic checkpoint regulator. Furthermore, unlike reported in mouse cells (Dobles et al., 2000) or human cancer cell lines (Kops et al., 2004 ) that loss of MAD2 leads to cell death, our results demonstrate that dominant-negative inactivation of the MAD2 protein provides a survival advantage for polyploid cells and their growth in soft agar in nonmalignant human epithelial cells. However, the fact that the MAD2DC-transfected cells displayed anchorage-independent growth only after challenged by DMBA suggests that a defective mitotic checkpoint alone may predispose human cells to carcinogen-induced malignant transformation, but not the direct cause of tumorigenicity.
CIN is frequently reported in prostate cancer specimens (Webb et al., 1996; Zitzelsberger et al., 1996; Deliveliotis et al., 2003) and is thought to be a major event during the transformation of normal prostate epithelium to prostate cancer (Phillips et al., 2001) . In addition, significant number of prostate cancer specimens and established cell lines show tetraploidy or near tetraploidy (Webb et al., 1996; Bernardino et al., 1997; Haapala et al., 2001) . In this study, our results that dominant-negative suppression of MAD2 function led to polyploidy in prostate epithelial cells, indicating that inactivation of mitotic checkpoint may be one of the first steps in the malignant progression of prostate cancer. Our results seemed to be contradictory to previous reports that the loss of MAD2-induced chromosomal instability was lethal (Dobles et al., 2000; Kops et al., 2004) . However, it is possible that unlike mouse cells or human cancer cells, the presence of HPV E6/E7 oncogenes in the Hpr1 cells in this study may provide an explanation for the controversy. As shown in Figure 1e , approximately 30% of the stable MAD2DC transfectants underwent senescence probably as the result of severe chromosomal missegregation. However, majority of the cells managed to overcome senescence and established a population of proliferating polyploid cells (Figures 1c and d) . In addition, after exposure to nocodazole, unlike the vector control, the MAD2DC cells were able to overcome a mitotic arrest, and undergo cell division (Figures 3a and b) . It is possible that the impaired p53/RB pathways induced by HPV E6/E7 oncogenes may provide survival advantage for the mitotic-defective MAD2DC cells by allowing cell cycle progression in the presence of chromosomal missegregation leading to polyploidy. In addition, partial function of both checkpoints, rather than complete loss of function, may act as a protector against severe losses or gains of genetic materials leading to promotion of cell survival in the presence of mitotic damage. It is also noted that the MAD2 deletion-induced cell death was suggested to be a result of severe loss of chromosomes (Dobles et al., 2000) , however, the viable MAD2 þ /À murine embryonic fibroblasts (MEF) cells demonstrated aneuploidy associated with gains of chromosomes (Michel et al., 2001) . Interestingly, a previous study on the MEF cells from viable MAD2À/Àp53À/À mice also reported gains of chromosomes and premature anaphase (Burds et al., 2005) . Since the Hpr-1 cells used in this study also harbor an impaired p53 response due to previous expression of HPV E6/E7 oncogenes (Choo et al., 1999) , the survival of cells with loss of MAD2 function may require the cooperation of additional genetic alterations such as an impaired p53 pathway. However, it is not clear how the HPV E6/E7 oncogenes cooperate with the mitotic checkpoint to promote cell survival or if it involves a p53/RB-independent process. Nevertheless, our results suggest a possible mechanism to explain the positive role of polyploidy in cell survival and development of malignancy.
However, similar to the reports on mouse cells (Fujiwara et al., 2005) , polyploidy alone in human prostate epithelial cells was not sufficient to induce malignant transformation because the MAD2DC cells displayed anchorage-independent growth only after exposure to DMBA (Figure 4 ). Although loss of chromosomes is reported to be a common event during malignant transformation (Kops et al., 2005) , it was not observed in the MAD2DC-agar cells (Figures 2 and 4c) . Instead, increased chromosomal rearrangements such as translocations were observed in MAD2DC-agar cells. It is possible that increased chromosomal structural changes may lead to further inactivation of tumor suppressor genes or activation of the growth-promoting pathways. To support this notion, we found that p53 function was completely abolished in the MAD2DC-agar cells while activation of the MAPK pathway was observed ( Figure 5 ). These genetic alterations may provide further growth advantage necessary for malignant transformation of MAD2DC cells.
In summary, we have demonstrated the significance of MAD2 inactivation in chromosomal instability in human prostate epithelial cells. Our results suggest that dominant-negative suppression of the binding between MAD2 and Cdc20 and MAD1 leads to polyploidy, which may predispose human cells to undergo malignant transformation. The evidence presented here provides a link between a compromised mitotic checkpoint and the malignant transformation of epithelial cells.
Materials and methods

Cell culture
Hpr-1, a human prostate epithelial cell line, immortalized by HPV 16 E6/E7 oncogenes (Choo et al., 1999) , was maintained in keratinocyte serum-free medium (KSFM) supplemented with 2% penicillin G/streptomycin (KSFM; Invitrogen, Carlsbad, CA, USA) at 371C with 5% CO 2 incubator.
Generation of stable pBabe/MAD2ÄC transfectants
The C-terminal-deleted form of MAD2 was amplified by PCR and the pBabe-MAD2Ä C plasmid was generated as described previously (Fung et al., 2006) . The stably MAD2Ä C-transduced Hpr-1-MAD2Ä C subline was obtained by selecting in 2 ı`g/ml puromycin (CalbioChem, San Diego, CA, USA) for 6 days and then cultured in KSFM medium. Empty pBabe vector-transfected Hpr-1 cells were also generated with the same protocol as a control. All the stable transfectants were generated from pool of more than 50 positive clones.
Metaphase spreading
Metaphase spread was prepared as previously described (Deng et al., 2003) . Chromosome number of at least 50 metaphase cells was determined by light microscopy with Â 400 magnification.
Spectral karyotyping SKY was performed by using the Applied Spectral Imaging kit (SkyPaint mixture, Applied Spectral Imaging, Migdal Ha' Emek, Israel) as described previously (Deng et al., 2004) . Chromosomal analysis was carried out using the SkyVision Imaging System equipped with a Zeiss Axiophot 2 fluorescence microscope (CarlZeiss, Oberkochen, Germany). At least 50 metaphase spreads were analysed for each cell line.
5-Bromo-2
0 -deoxyuridine incorporation assay The BrdU incorporation rate was examined using a protocol described previously (Cheung et al., 2005) . At least 500 cells were counted from three random fields captured by a Zeiss Axiophot fluorescence microscopy (CarlZeiss) under Â 200 magnification and each experiment was repeated three times.
3-2,5-Diphenyltetrazolium bromide assay Cell proliferation rate was determined using the Cell Proliferation Kit 1 (MTT; Roche Diagnostics, Indianapolis, IN, USA) as described previously (Cheung et al., 2005) . The cell proliferation rate was plotted by dividing the mean of absorbance at different time points with time '0' and the error bars indicated s.d.
b-Galactosidase staining
The detailed experimental procedures were described previously (Wang et al., 1998) Centrosome immunostaining Detailed experimental procedures were described previously (Ouyang et al., 2001) . Immunofluorescence microscopy was performed on a Zeiss Axiophot System (CarlZeiss) under Â 1000 magnification. The number of centrosomes was counted in at least 1000 cells in each sample and the results represent the average from at least two experiments with s.d. as error bars.
Cell cycle analysis
Flow cytometry was preformed as described (Cheung et al., 2005) .
Western blotting Detailed experimental procedures were described previously (Cheung et al., 2005) . The details of the primary antibodies used are as follows: MAD2 (BD Biosciences, Franklin Lakes, NJ, USA), Flag (Sigma, St Louis, MD, USA), cyclin A (Santa Cruz Biotechnology, San Diego, CA, USA), cyclin B1 (Santa Cruz Biotechnology), phospho-histone H3 (Ser10) (Upstate Cell Signaling Solution, Lake Placid, NY, USA), p53 (DakoCytomatin, Glostrup, Denmark), actin (Santa Cruz Biotechnology), p21
Waf1 (DakoCytomatin), phospho-histone H2A.X (Ser139) (Upstate cell signaling solutions), phospho-MEK1/2 (Ser217/221) (Cell Signaling Technology, Beverly, MA, USA) or phospho-p42/44 MAP Kinase (Thr202/Tyr204) (Cell Signaling Technology) for 1 h.
Soft agar colony-forming assay A total of 0.6% agar (Sigma) in RPMI-1640 medium (Invitrogen) supplemented with 10% fetal bovine serum was poured into each well of 12-well culture plates. After solidification, equal amount of cell suspension (containing 20 000 or 2000 cells) was mixed with 0.3% soft agar and laid on top of the 0.6% agar in each well to allow solidify. Then 1 ml RPMI-1640 medium was added and the wells were placed at 371C and 5% CO 2 incubator for 6-8 weeks until colonies were visible. The number of colonies in each well was counted and the colony-forming ability was calculated by dividing the number of cells seeded with total number of colonies in each well. Two wells were set up for each cell line and results represent average of two experiments.
In vitro transformation assay Cells were treated with either acetone as a solvent control or DMBA (500 ng/ml; 1000 ng/ml; Sigma) for 3 days. Then the cells were treated with either dimethyl sulfoxide as a solvent control or TPA (100 ng/ml, Sigma) for 10 days. The untreated, solvent-treated alone, TPA-treated alone and DMBA-treated alone cells were also set up as controls. The cells were then passaged continuously in fresh medium for three passages and tested for colony-forming ability in soft agar. Results represent average of two experiments.
RNA extraction and direct sequencing RNA was extracted by TRIzol reagent following the manufacturer's protocol (Invitrogen). Briefly, homogenized cells in TRIzol reagent was mixed with 0.2 ml chloroform in 1 ml solution. After shaking vigorously and centrifugation, a colorless upper aqueous phase containing RNA was separated and mixed with 0.5 ml of isopropyl alcohol to precipitate the RNA. Then RNA was collected by centrifugation and washed twice with 1 ml of 70% ethanol. Finally, the RNA was dissolved in diethylpyrocarbonate-treated water. First strand cDNA was synthesized from the RNA sample by SuperScript II RT kit (Invitrogen) with 5 mg of RNA per sample. Primers for full-length coding sequence of p53 (forward primer: 5 0 -AAGGATCCAAGAGGAGCCGCAGT-3 0 ; reverse primer: 5 0 -GCGAATTCTCAGTCTGAGTCAGG-3 0 ) and primers for amplifying H-ras, N-ras and K-ras genes (H-Ras: forward primer: 5 0 -ATGACGGAATATAAGCTGGT-3 0 ; reverse primer: 5 0 -AGGAAGCCCTCCCCGGTGCG-3 0 ; K-Ras: forward primer: 5 0 -ATGACGGAATATAAGCTGGT-3 0 ; reverse primer: 5 0 -CACAAAGAAAGCCCTCCCCA-3 0 ; N-Ras: forward primer: 5 0 -ATGACTGAGTACAAACTGGT-3 0 ; reverse primer: 5 0 -GTAGAGGTTAATATCCGCAA-3 0 ) were used as described (Di et al., 2006) . The PCR conditions were as follows: for P53: 35 cycles of 941C for 1 min, 501C for 1 min, 721C for 2 min; for Ras: 35 cycles of 941C for 45 s, 501C for 45 s, 721C for 1 min. The amplified target sequences were then purified using Qiagen purification kit (Qiagen, Valencia, CA, USA) and sequenced commercially. The sequences were then analysed and compared to the Genebank information (NM_000546 for p53, NM_033360 for K-ras, NM_005343 for H-ras and NM_002524 for N-ras).
